Basel, 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented... Read more
Basel, 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented... Read more
Basel, 23 June 2017 Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia,... Read more
Basel, 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed sustained benefit in progression-free survival of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatment regardless of chemotherapy regimens People with follicular lymphoma who received Gazyva/Gazyvaro-based treatment reported improvement in health-related quality of... Read more
Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan* Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan... Read more
Basel, 23 June 2017 New data at EAN show Roche’s OCREVUS™ (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis OCREVUS increased the number of patients with relapsing MS (RMS) and primary progressive MS (PPMS) who maintained No Evidence of Progression or Active Disease (NEPAD) versus Rebif (interferon beta-1a)... Read more
Basel, 14 June 2017 Roche’s employee-driven philanthropic campaign sets new record 145 company sites unite for Roche Children’s Walk to raise funds for children’s projects around the world Children’s Walk exemplifies Roche’s commitment to sustainable, philanthropic projects Money raised goes to initiatives in more than 90 communities for efforts related to education and health initiatives... Read more
Basel, 06 June 2017 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2017 Tuesday, 1st August 2017 We are pleased to invite you to an analyst event on Tuesday, 1st August 2017 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab... Read more
Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more
Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more